[1] Siegel R L, Miller K D, Jemal A. Cancerstatistics[J]. CA:A Cancer Journal for Clinicians, 2017, 67(1):7-30.
[2] Kakimi K, Karasaki T, Matsushita H, et al. Advances in personalized cancer immunotherapy[J]. Breast Cancer, 2017, 24(1):16-24.
[3] Ludin A, Zon L I. Cancer immunotherapy:The dark side of PD-1 receptor inhibition[J]. Nature, 2017, 552(7683):41-42.
[4] Wartewig T, Kurgyis Z, Keppler S, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis[J]. Nature, 2017, 552(7683):121-125.
[5] Jennifer C F. Powerful new cancer drugs are saving lives, but can also ignite diabetes or other autoimmune conditions[EB/OL]. (2017-11-15)[2017-12-05]. http://www.sciencemag.org/news/2017/11/powerful-new-cancer-drugs-are-saving-livescan-also-ignite-diabetes-or-other-autoimmune.
[6] Vétizou M, Pitt J M, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J]. Science, 2015, 350(6264):1079-1084.
[7] Botticelli A, Zizzari I, Mazzuca F, et al. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment[J]. Oncotarget, 2017, 8(5):8890-8899.
[8] KYMRIAH (tisagenlecleucel)[EB/OL]. (2017-08-30)[2017-12-05]. https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM574106.pdf
[9] Mullard A. FDA approves first CAR T therapy[J]. Nature Reviews. Drug Discovery, 2017, 16(10):669.
[10] YESCARTA (axicabtagene ciloleucel)[EB/OL]. (2017-10-18)[2017-12-05]. https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM581259.pdf.
[11] Kingwell K. CAR T therapies drive into new terrain[J]. Nature Reviews. Drug Discovery, 2017, 16(5):301-304.
[12] Pembrolizumab (Keytruda) 5-10-2017[EB/OL]. (2017-05-10)[2017-12-05]. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm558048.htm.
[13] Garber K. Oncologists await historic first:A pan-tumor predictive marker, for immunotherapy[J]. Nature Biotechnology, 2017, 35(4):297-298.
[14] Dudley J C, Lin M T, Le D T, et al. Microsatellite instability as a biomarker for PD-1 blockade[J]. Clinical Cancer Research:An Official Journal of the American Association for Cancer Research, 2016, 22(4):813-820.
[15] Melissa H. Immunotherapy drug opens a new era of precision medicine for cancer[EB/OL]. (2017-05-26)[2017-12-05]. http://www.latimes.com/science/sciencenow/la-sci-sn-cancerimmunotherapy-drug-20170526-story.html?from=singlemessage&isappinstalled=0.
[16] Liu L, Li X, Wang J, et al. Two distant catalytic sites are responsible for C2c2 RNase activities[J]. Cell, 2017, 168(1/2):121-134.
[17] Eyquem J, Mansilla-Soto J, Giavridis T, et al.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection[J]. Nature, 2017, 543(7643):113-117.
[18] Patel S J, Sanjana N E, Kishton R J, et al. Identification of essential genes for cancer immunotherapy[J]. Nature, 2017, 548(7669):537-542.
[19] Wan L, Wen H, Li Y, et al. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia[J]. Nature, 2017, 543(7644):265-269.
[20] Manguso R T, Pope H W, Zimmer M D, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target[J]. Nature, 2017, 547(7664):413-418.
[21] Committee on human gene editing:Scientific, medical, and ethical considerations. Human Genome Editing:Science, Ethics, and Governance (2017)[R]. Washington D C:National Academies of Sciences, Engineering, and Medicine, 2017.
[22] Ma H, Marti-Gutierrez N, Park SW, et al. Correction of a pathogenic gene mutation in human embryos[J]. Nature, 2017, 548(7668):413-419.
[23] Jiang C, Mei M, Li B, et al. A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo[J]. Cell Research, 2017, 27(3):440-443.
[24] Basu S, Adams L, Guhathakurta S, et al.A novel tool for monitoring endogenous alpha-synuclein transcription by NanoLuciferase tag insertion at the 3'end using CRISPR-Cas9 genome editing technique[J]. Scientific Reports, 2017, 8:45883.
[25] O'Neil N J, Bailey M L, Hieter P. Synthetic lethality and cancer[J]. Nature Reviews. Genetics, 2017, 18(10):613-623.
[26] Banerjee S, Kaye SB, Ashworth A.Making the best of PARP inhibitors in ovarian cancer[J]. Nature Reviews. Clinical Oncology, 2010, 7(9):508-519.
[27] FDA approves PARP inhibitor for ovarian cancer[J]. Nature Biotechnology, 2017, 35(5):398.
[28] Mullard A. Synthetic lethality screens point the way to new cancer drug targets[J]. Nature Reviews. Drug Discovery, 2017, 16(10):736.
[29] Wang T, Yu H, Hughes N W, et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras[J]. Cell, 2017, 168(5):890-903.
[30] Barbieri I, Tzelepis K, Pandolfini L, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control[J]. Nature, 2017, 552(7683):126-131.
[31] MIT Technology Review. 10 Breakthrough Technologies 2017[EB/OL]. (2017-02-24)[2017-12-05]. https://www.technologyreview.com/lists/technologies/2017/.
[32] Spark Therapeutics. FDA advisory committee unanimously recommends approval of investigational LUXTURNATM (voretigeneneparvovec) for patients with Biallelic RPE65-mediated Inherited retinal disease[EB/OL]. (2017-10-12)[2017-12-05]. http://ir.sparktx.com/news-releases/news-release-details/fda-advisory-committee-unanimously-recommends-approval.
[33] Bennett J, Wellman J, Marshall K A, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations:A follow-on phase 1 trial[J]. Lancet, 2016, 388(10045):661-672.
[34] Russell S, Bennett J, Wellman J A, et al. Efficacy and safety of voretigeneneparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy:A randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2017, 390(10097):849-860.
[35] Morrison C. Landmark gene therapy poised for US approval[J]. Nature Reviews. Drug Discovery, 2017, 16(11):739-741.
[36] Sangamo Therapeutics. Corporate Presentation[EB/OL]. (2017-08-21)[2017-12-05]. https://investor.sangamo.com/presentations.
[37] Jocelyn K. A human has been injected with gene-editing tools to cure his disabling disease. Here's what you need to know[EB/OL]. (2017-11-15)[2017-12-05]. http://www.sciencemag.org/news/2017/11/human-has-been-injected-geneediting-tools-cure-his-disabling-disease-here-s-what-you.
[38] Mendell J R, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy[J]. The New England journal of medicine, 2017, 377(18):1713-1722.
[39] Silver D, Schrittwieser J, Simonyan K, et al. Mastering the game of Go without human knowledge[J]. Nature, 2017, 550(7676):354-359.
[40] Baskin I I, Winkler D, Tetko I V. A renaissance of neural networks in drug discovery[J]. Expert Opinion on Drug Discovery, 2016, 11(8):785-795.
[41] Mullard A. The drug-maker's guide to the galaxy[J]. Nature, 2017, 549(7673):445-447.
[42] Smalley E. AI-powered drug discovery captures pharma interest[J]. Nature Biotechnology, 2017, 35(7):604-605.
[43] Novel drug approvals for 2017[EB/OL]. (2017-11-30)[2017-12-05]. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm.
[44] Hunter N L, Rao G R, Sherman R E. Flexibility in the FDA approach to orphan drug development[J]. Nature Reviews. Drug Discovery, 2017, 16(11):737-738.
